GS

Gudiya Singh

Active Director Director DIN 08462347
DIN 08462347 First appointment May 2019 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2019
Shareholding value •••• Premium profile

About Gudiya Singh

Data last updated:

Gudiya Singh is a Director at Genovia Plus Pharmaceuticals Private Limited (since 2019). The company operates in Healthcare. Genovia Plus Pharmaceuticals Private Limited reported revenue of ₹27.2 Lakh (FY 2020).

DIN 08462347
Primary Designation Director
Industry Healthcare
First Appointment 24 May 2019
Oldest Company Age 11 yrs
Largest company Genovia Plus Pharmaceuticals Private Limited · ₹27.2 Lakh (FY 2020)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 May 20192015₹27.2 Lakh (FY 2020)Active

Board colleagues of Gudiya Singh

Directorship timeline

Open interactive timeline →
Genovia Plus Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Gudiya Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gudiya Singh

Gudiya Singh currently holds 1 directorship: Genovia Plus Pharmaceuticals Private Limited (Director, since 24 May 2019, revenue ₹27.2 Lakh (FY 2020)).

Gudiya Singh was first appointed on 24 May 2019 as Director at Genovia Plus Pharmaceuticals Private Limited.

The current boards of Gudiya Singh's companies include Manish Mangla Singh (Genovia Plus Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available